Univariate analysis of impact of sirolimus on CMV reactivation among MMF and PTCy recipients before day 100
| MMF . | . | . | . | . | . |
|---|---|---|---|---|---|
| CMV reactivation before d 100 . | Number of patients . | Number of patients with reactivation . | Sirolimus . | HR (95% CI) . | P . |
| >0 IU/mL | 351 | 261 | No | 1 | |
| 63 | 39 | Yes | 0.65 (0.47-0.89) | .007 | |
| ≥250 IU/mL | 351 | 146 | No | 1 | |
| 63 | 15 | Yes | 0.51 (0.30-0.87) | .013 | |
| ≥1000 IU/mL | 351 | 61 | No | 1 | |
| 63 | 3 | Yes | 0.25 (0.08-0.80) | .019 |
| MMF . | . | . | . | . | . |
|---|---|---|---|---|---|
| CMV reactivation before d 100 . | Number of patients . | Number of patients with reactivation . | Sirolimus . | HR (95% CI) . | P . |
| >0 IU/mL | 351 | 261 | No | 1 | |
| 63 | 39 | Yes | 0.65 (0.47-0.89) | .007 | |
| ≥250 IU/mL | 351 | 146 | No | 1 | |
| 63 | 15 | Yes | 0.51 (0.30-0.87) | .013 | |
| ≥1000 IU/mL | 351 | 61 | No | 1 | |
| 63 | 3 | Yes | 0.25 (0.08-0.80) | .019 |
| PTCy . | . | . | . | . | . |
|---|---|---|---|---|---|
| CMV reactivation before d 100 . | Number of patients . | Number of patients with reactivation . | Sirolimus . | HR (95% CI) . | P . |
| >0 IU/mL | 36 | 25 | No | 1 | |
| 8 | 6 | Yes | 1.22 (0.51-2.91) | .651 | |
| ≥250 IU/mL | 36 | 17 | No | 1 | |
| 8 | 5 | Yes | 1.31 (0.53-3.22) | .556 |
| PTCy . | . | . | . | . | . |
|---|---|---|---|---|---|
| CMV reactivation before d 100 . | Number of patients . | Number of patients with reactivation . | Sirolimus . | HR (95% CI) . | P . |
| >0 IU/mL | 36 | 25 | No | 1 | |
| 8 | 6 | Yes | 1.22 (0.51-2.91) | .651 | |
| ≥250 IU/mL | 36 | 17 | No | 1 | |
| 8 | 5 | Yes | 1.31 (0.53-3.22) | .556 |